ArticleJournal of Cancer2021

Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy.

Yanjuan He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.